A distinct form of autosomal recessive T − B − severe combined immunodeficiency disease occurs with a high frequency among Athabascan-speaking Native Americans (SCIDA), including Navajo and Apache Indians from the southwestern US and Dene Indians from the Canadian Northwest Territories. The SCIDA gene has been linked to markers on chromosome 10p although its identity and role in the pathogenesis of this disease are unknown. We report our experience in treating 18 Navajo and Dene children with SCIDA between 1984 and 1999; 16 underwent bone marrow transplants (BMT). All children were symptomatic within 2 months of birth, had the T − B − NK + SCID phenotype and 67% presented with oral and/or genital ulcers. Three children had evidence of maternal engraftment prior to transplant. Two children died shortly after diagnosis. Three children required more than one BMT and 12 are alive with T cell reconstitution at a median followup of 7 years. Three children developed normal B cell immunity, two of whom received ablative conditioning therapy with either radiation or busulfan. Three of the four children who died received therapy with either radiation or busulfan and two of eight long-term survivors who were also recipients of cytotoxic chemotherapy have failed to develop secondary teeth. These results demonstrate the efficacy of BMT in treating infants with this distinct form of SCID, although B cell reconstitution remains a problem even with HLAmatched donors. Without conditioning, T cell engraftment is likely when closely HLA-matched donors are used. With T cell depletion of haplocompatible marrow, conditioning with immunosuppressive therapy may be necessary; however, children with SCIDA who were treated with intensive immunosuppressive and 
A phenotypically distinct form of autosomal recessive T − B − severe combined immunodeficiency disease (SCID) occurs with a high frequency among Athabascan-speaking Native Americans (SCIDA) including the Navajo and Apache Indians in the southwestern United States. 1 The incidence of this disorder is 52 cases per 100 000 live births among the Navajo with an estimated disease gene frequency of 2.1%. 2 Most affected infants with SCIDA present in early infancy with pneumonia or other serious infections. Chronic diarrhea and failure to thrive are also common at the time of presentation. A clinical feature that appears unique to this form of SCID is the development of severe oral and/or genital ulcerations of unknown etiology. 3, 4 Immunologic features include a marked reduction or absence of circulating T and B cells (T − B − phenotype) and severe impairment of T and B cell function. Natural killer (NK) cell numbers and function are preserved. The genetic defect responsible for SCIDA has not yet been determined although we have mapped the gene to a 6.5 cM region on chromosome 10p, 5 and more recently, have identified a defect in DNA V(D)J recombination in a cell line from a child with SCIDA. 6 Bone marrow transplantation (BMT) is the only curative treatment for SCID that is otherwise fatal in infancy. Techniques for successfully depleting haploidentical parental marrow when an HLA-matched sibling is unavailable have permitted the use of BMT for virtually all children with SCID. [7] [8] [9] [10] [11] [12] However, there is significant variability among the different types of SCID in terms of ease of engraftment and the need for conditioning therapy, especially with T cell-depleted HLA mismatched grafts. 8, 9, 11 In this report, we describe our experience in treating 18 children with SCIDA including their clinical presentation, response to BMT, immune reconstitution and long-term follow-up.
Materials and methods

Patients
Eighteen children with SCIDA were referred to the University of California San Francisco (UCSF) between 1984 and 1999 for evaluation and therapy. All patients were Athabascan-speaking Native Americans. Fifteen patients were of Navajo descent and lived in the southwestern United States and three were from the Athabascan-speaking Dene Nation from the Canadian Northwest Territories (Table 1) . Protocols and consents were approved by the UCSF Committee on Human Research, the Navajo Area Indian Health Service, and the Navajo Nation Institutional Review Board.
Lymphocyte phenotyping
Lymphocyte phenotyping was performed for diagnosis and at 1 to 3 month intervals post transplant. T and B cell lymphocyte subsets were quantified by flow cytometric analysis using fluorescent-conjugated monoclonal antibodies to human cell surface antigens (CD3, CD4, CD8, CD16, CD19, CD56) and a FACScan analyzer (Becton Dickinson, Mountain View, CA, USA).
Lymphocyte function
Lymphocyte proliferative responses to phytohemagglutinin (PHA), alloantigen in mixed lymphocyte culture (MLC), candida antigen and tetanus antigen were measured by the incorporation of 3 H-thymidine as previously described. 11, 13 Natural killer (NK) cell function was measured using a standard cell lysis assay with 51 Cr-labeled NK targets (K562) and specific cell lysis calculated.
14 Briefly, 1 × 10 6 
Hematopoietic stem cell transplants
Donor selection: Donors were selected from the affected infant's first degree relatives. The criteria for donor selection were (in order of preference): HLA compatibility, cytomegalovirus (CMV) serology, and blood type. Parental donors were used for the initial BMT in seven cases and sibling donors in the remaining nine cases ( Table 2 ). There were six genotypically matched sibling donors. Of the remaining 10 haplocompatible donors one was a phenotypically matched parent, three were Dr␤1-matched siblings, and the remaining six were haplocompatible parents mismatched at least at one Dr␤1 gene.
Conditioning therapy: Thirteen of 16 patients received some type of conditioning therapy prior to the initial BMT ( Table 2 ). Of these, two patients received horse antithymocyte globulin (ATG) 80 mg/kg, nine received cyclophosphamide (Cy) 200 mg/kg and ATG 80 mg/kg, and two patients received Cy 120 mg/kg and ATG 90 mg/kg with either busulfan 16 mg/kg (one patient) or total body Table 2 Outcome of bone marrow stem cell transplants for 16 children with SCIDA by donor match and age at transplant GVHD prophylaxis: Chemoprophylaxis for graft-versushost disease (GVHD) for the initial transplant consisted of methotrexate (MTX) and cyclosporin A (CsA) in seven patients, CsA alone for two patients, prednisone/CsA for one patient, and no GVHD prophylaxis for six patients ( Table 2) .
T cell depletion: T cell depletion of bone marrow was performed with soybean agglutinin (SBA) and sheep erythrocyte (SRBC) rosetting as previously described. 7 In one patient mismatched with the donor at two class I HLA antigens, T cells were depleted with an anti-CD2 monoclonal antibody conjugated to magnetic beads (Dynal, Oslo, Norway). Two patients received parental peripheral blood stem cells (PBSC) which were harvested after mobilization with 4 days of granulocyte colony-stimulating factor (G-CSF) administered two times per day (5 g/kg/dose). CD34 + cells were selected from the leukapheresis using the Isolex 300 (Nexcel, Irvine, CA, USA) and a further T cell depletion was performed by negative selection using magnetic beads conjugated with a monoclonal anti-CD3 antibody (OKT3). 16 The final preparations contained Ͻ0.1% CD3 + cells and the dose of T cells was Ͻ7 × 10 4 /kg.
Engraftment studies: Engraftment was determined by HLA and non-HLA DNA typing of peripheral blood mononuclear cells by polymerase chain reaction using sequencespecific probes for DR, or primers for informative non-HLA polymorphisms. Where appropriate, engraftment was also determined in lymphocyte preparations by fluorescent in situ hybridization (FISH) using X and Y chromosomespecific probes.
Results
Clinical and laboratory characteristics
The clinical findings at diagnosis in the 18 children are summarized in Table 1 . One infant was diagnosed in utero based upon haplotype analysis for the disease gene on chromosome 10. 5 Seven infants were diagnosed at birth (including the one who underwent prenatal diagnosis) because of the presence of a previously diagnosed sibling or relative. A family history of infant death consistent with SCID was present in seven of the kindreds. The remaining infants presented in early infancy with pneumonia or other serious infections. Chronic diarrhea and failure to thrive occurred in each of these infants. Twelve of the 18 patients developed deep and painful ulcerative lesions of the oral mucosa or genitalia prior to, or within 1 month after BMT. 4 All of the patients had an absent thymus on chest X-ray. Three of the recipients (PIN 13, 15 and 18) had evidence of engraftment of maternal hematopoietic cells prior to BMT; in two cases this was associated with grade 2 cutaneous GVHD.
Lymphopenia (absolute lymphocyte count = 507 Ϯ 315/l) was present in all of the patients including three children with maternally engrafted cells (Table 3) . With the exception of those three children, the percent of lymphocytes that were CD3 + was very low to absent (2.4 Ϯ 2.7%). B cells (CD19 + ) were also very low to absent in all of the patients (1.0 Ϯ 1.2%). Immunoglobulin levels were low to absent in those children in whom they were measured (data not shown). Lymphocyte proliferative responses to mitogen and alloantigen were also low to absent and NK function was normal in those patients in whom it was measured (31 Ϯ 10%, n = 3).
Post-transplant course
Two children were too ill to undergo a transplant, one with CMV pneumonia and acute respiratory distress syndrome (PIN 1), and one with disseminated CMV disease including encephalitis (PIN 4); both died within a week of arrival at UCSF. In the remaining 16 patients who received transplants, evidence for donor cell engraftment occurred within 4 weeks of BMT and no deaths occurred during the first 100 days. The expected spectrum of infectious complications was observed during the immediate post-BMT period (Table 2) . Four patients (PIN 5, 6, 12, 14) developed a transient type II renal tubular acidosis within the first 3 months after BMT. No patient developed hepatic venoocclusive disease or acute GVHD greater than grade II.
Twelve of the 18 patients (67%) are alive. Projected survival for those who received a transplant is 77% at 5 years post BMT (Figure 1 ). In addition to the two children who did not receive a transplant, one patient (PIN 6) died 10 months after BMT of bacterial sepsis, one patient (PIN 7) died 5.5 years post BMT of severe hemolytic uremic syndrome and chronic lung disease, and two patients (PIN 12, 15) died of autoimmune hemolytic anemia at 5 months and 7.5 years post initial BMT, respectively. 17 All four of these children were recipients of haplocompatible T cell-depleted parental grafts pre-conditioned with cyclophosphamide alone (one patient), cyclophosphamide and busulfan (one patient), or cyclophosphamide and TBI (two patients).
Immune reconstitution
Fifteen of the 16 transplant recipients achieved durable T cell engraftment and 11/16 developed normal T cell function following the initial BMT (Table 4 ). The kinetics of T cell numbers and functional reconstitution for these patients are shown in Figure 2 . Evidence for donor cell and/or T cell engraftment first appeared at a mean (Ϯ s.d.) of 25 Ϯ 8 days post BMT. Normalization of T cell numbers and proliferative responses to alloantigen occurred in the majority of evaluable patients by 6 months and 1 year post BMT, respectively (Figure 2) . Similar results were seen in the response to PHA (data not shown). Three patients (PIN 2, 7, 12) required between one and four additional bone marrow or peripheral blood stem cell infusions or boosts 18 because of loss of immune function and recurrence of mouth ulcers (PIN 2), failure to engraft following the initial 707 Percent cytotoxicity at 50:1 (n = 3 patients).
Cumulative proportion surviving
Post BMT (months) transplant (PIN 7), or inadequate T cell reconstitution (PIN 7, 12) . This was accomplished by either using the other parent as the donor, a myeloablative conditioning regimen, or a repeat stem cell infusion (boost) without conditioning ( Table 2) .
Bone Marrow Transplantation Engraftment of donor B cells with normalization of serum immunoglobulin levels occurred in three patients (PIN 3, 7, 8) , two of whom received myeloablative conditioning therapy (busulfan or TBI). Of the six recipients of HLA genotypically matched marrow, only one (PIN 3) recovered B cell immunity; none of these patients were treated with myeloablative conditioning therapy. The remaining patients continue to require replacement intravenous immune globulin (IVIG) infusions and have no detectable B cells in the peripheral circulation despite normal T cell reconstitution (Table 4) .
Long-term follow-up
Eleven children were followed for at least 4 years post BMT (median 7.2 years). Growth was normal in the majority of the patients. The three exceptions were children who were conditioned with either busulfan or TBI containing regimens or in one case, cyclophosphamide alone. Developmental testing (Stanford-Binet composite scores) averaged 96 Ϯ 12 (median 95). One child (PIN 7) developed moderately severe restrictive lung disease secondary to frequent pneumonias. She had received 700 cGy TBI with 50% shielding of the lungs as conditioning therapy resulting in full T and B cell reconstitution. A lung biopsy showed no evidence of chronic GVHD. She ultimately died following an episode of E. coli-related hemolytic uremic syndrome. Another child (PIN 10) who was conditioned with cyclophosphamide and ATG developed multiple alveolar hemorrhages at 5 years after HLAmatched sibling transplant. An open lung biopsy revealed no evidence for GVHD. She responded to immunosuppressive therapy. Interestingly, two children (PIN 5,8) out of eight who were followed at least 5 years and who had received cytotoxic conditioning failed to develop secondary teeth. We know of another child with SCIDA transplanted at another center who received chemotherapy conditioning pre-transplant and who also has failed to develop secondary teeth (Diana Hu, personal communication).
Discussion
SCIDA is a clinically and genetically distinct form of autosomal recessive T − B − SCID. The onset of symptoms is uniformly early compared to other forms of SCID, with most SCIDA infants becoming symptomatic within the first 3 months of life. Diarrhea and failure to thrive are prominent features and the spectrum of infections seen is similar to that in other forms of SCID. 19 The occurrence of deep oral and genital ulcers is a unique clinical finding which is specific to this form of SCID. 3, 4 The presence of normal numbers of functional NK cells despite a marked reduction in T and B cells is another characteristic feature of this disorder. The other known autosomal-inherited SCIDs with the T − B − phenotype have been reported in children with either mutations in the recombinase activating genes of the T and B cell receptors (RAG1 and 2), 20 or in the DNA repair phase of V(D)J recombination. 21 The specific gene in this latter form of T − B − SCID has not been identified. Although the genetic defect responsible for SCIDA is unknown, we have linked the disease gene to markers on chromosome 10p. 5 We have also ruled-out genes known to be associated with T cell receptor recombination as well as other genes that might cause a similar T and B cell immune defect. 5 Recently, we found that a cell line from a patient with SCIDA demonstrated an absence of V(D)J codingjoint formation which is part of the DNA repair process of V(D)J recombination. 6 Bone marrow transplantation from HLA-identical sibling donors has been used successfully for the treatment of SCID. 9, 10 The 75% long-term survival following BMT for SCIDA that we have seen compares favorably with reported survival data after BMT for other forms of SCID. 9, 22 Our results might reflect the early age at transplantation (mean 2.3 months) and the relatively short interval between diagnosis and BMT (mean 1.5 months). This was facilitated by the diagnosis of seven infants at birth with early transplantation prior to the onset of serious infections. The use of non-myeloablative conditioning regimens in 14 of 16 initial transplants also probably contributed to the absence of mortality in the immediate BMT period and subsequent long-term survival.
The use of an immunosuppressive conditioning regimen or no conditioning resulted in T cell but not B cell reconstitution in 11 of 12 initial transplants. The requirement of myeloablative conditioning for B cell reconstitution in many children with SCID has previously been reported. 22, 23 This is further illustrated by the finding that two of the three SCIDA patients to achieve B cell reconstitution in this series received myeloablative conditioning regimens. The failure to reconstitute B cell immunity in T − B − SCID suggests a more complex maturation process for the B cell lineage without the same apparent selective advantage that appears to exist for donor T cells. Sub-optimal immune reconstitution can be a significant problem after haploidentical T cell-depleted BMT for SCID despite the encouraging survival data reported here. However, myeloablative preparative regimens, while facilitating engraftment and immune reconstitution, also significantly increase transplant morbidity and mortality especially in young infants. Our results support the use of either no conditioning or immunosuppressive conditioning alone for the initial BMT in children with SCIDA. Donor marrow 'boosts' or repeat BMT with myeloablative conditioning should be reserved for those cases in which the initial procedure results in inadequate T cell immune reconstitution or graft failure, respectively.
The long-term outcome post transplant for the majority of these patients has been quite good with respect to growth and development. Certain complications including pulmonary alveolar hemorrhage in one patient and the absence of secondary teeth in three children are unexplained and not typically seen in other forms of SCID although this latter complication has recently been reported in three SCID patients. 24 Whether or not the dental complications in the SCIDA patients are related to their underlying genetic defect or their conditioning therapy remains to be determined.
In summary, bone marrow stem cell transplantation results in long-term disease-free survival for the majority of children with SCIDA. Furthermore, it is most successful if performed early in life and can be safely accomplished with immunosuppressive conditioning alone when a haplocompatible relative is used, and no conditioning when an HLA matched donor is available.
